Neurocrine Biosciences, Inc. Financials

Market Capitalization $12.78 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	43.91
Forward PE	20.79
Price to Sales TTM	$5.30
Price to Book MRQ	$5.04
Enterprise to Revenue	4.97
Enterprise to EBITDA	22.62

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	12.68%
Operating Margin	4.14%
Return on Assets TTM	8.75%
Return on Equity TTM	12.43%

Income Statement

Revenue TTM	$2,412,600,064
Revenue per Share TTM	$24.04
Quarterly Revenue Growth	11.10%
Gross Profit TTM	$1,542,000,000
EBITDA	$509,400,000
Net Income to Common TTM	$305,800,000
Diluted EPS TTM	$2.94
Quarterly Earnings Growth YoY	-81.80%

Balance Sheet

Total Cash MRQ	$943,500,032
Total Cash per Share MRQ	$9.53
Total Debt MRQ	$
Total Debt to Equity MRQ	19.45
Current Ratio MRQ	3.13
Book Value per Share MRQ	$25.61

Cash Flow

Operating Cash Flow TTM	$529,900,000
Levered Free Cash Flow TTM	$235,475,008

NBIX Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	99,400,000
Float Shares	97,783,178
Avg 10 Volume	895,110
Avg 30 Volume	None
Shares Short	3,495,103
Short Ratio	3.39
Short % of Shares	4.72%
% Held by Insiders	1.06%
% Held by Institutions	98.66%

Stock Price Summary

Beta	0.24
Fifty Two Week Low	$84.23
Fifty Two Week High	$157.98
Fifty Two Week Change	-7.72%
Day 50 MA	$120.60
Day 200 MA	$121.56

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	1995-12-29
Last Split Factor
Last Split Date